InvestorsHub Logo
Followers 48
Posts 5518
Boards Moderated 0
Alias Born 09/04/2009

Re: lizzy241 post# 373744

Thursday, 03/24/2022 2:42:15 PM

Thursday, March 24, 2022 2:42:15 PM

Post# of 425931
lizzy, for EU, it's either GIA or partnership as you can't force a buyer if nobody is willing to buy. JT explained that partnership didn't make sense because V would become the 4th or 5th drug in Euro BP's sales bag (think Kowa) and as a result, the resulting shared profit wouldn't be much. For an example of EU partnership gone wrong, just look at the pathetic sales of ESPR's cardio drug in EU with its EU partner Daiichi Sankyo.

https://www.esperion.com/news-releases/news-release-details/esperion-announces-agreement-daiichi-sankyo-europe-dse
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News